Abstract
The development of new antimicrobial agents for the treatment of infectious diseases remains challenging due to the increasing impact of antibiotic resistance. Since salicylanilides and esters of pyrazine-2-carboxylic acid have been described as potential antimicrobials, we have designed and synthesized a series of 2-(phenylcarbamoyl)phenyl pyrazine-2-carboxylates. These were evaluated in vitro for the activity against fungi and Gram-positive and Gram-negative bacteria. All derivatives showed significant antibacterial activity against Gram-positive strains (MIC ≥ 0.98 µmol/L) including methicillin-resistant Staphylococcus aureus. The most active molecule was 5-chloro-2-(3-chlorophenylcarbamoyl)phenyl pyrazine-2-carboxylate. With one exception these esters were at least partly active against fungi tested strains, in particular against mould strains (MIC ≥ 1.95 µmol/L). The most active antifungal agent overall proved to be 2-(4-bromophenylcarbamoyl)-4-chlorophenyl pyrazine-2-carboxylate.
Keywords: Antibacterial activity, antifungal activity, in vitro activity, pyrazine-2-carboxylic acid ester, salicylanilide, salicylanilide ester, salicylanilide, Clostridium difficile, Staphylococcus aureus, MRSA, fungal pathogens
Medicinal Chemistry
Title:In Vitro Antibacterial and Antifungal Activity of Salicylanilide Pyrazine-2- carboxylates
Volume: 8 Issue: 4
Author(s): Martin Kratky, Jarmila Vinsova and Vladimir Buchta
Affiliation:
Keywords: Antibacterial activity, antifungal activity, in vitro activity, pyrazine-2-carboxylic acid ester, salicylanilide, salicylanilide ester, salicylanilide, Clostridium difficile, Staphylococcus aureus, MRSA, fungal pathogens
Abstract: The development of new antimicrobial agents for the treatment of infectious diseases remains challenging due to the increasing impact of antibiotic resistance. Since salicylanilides and esters of pyrazine-2-carboxylic acid have been described as potential antimicrobials, we have designed and synthesized a series of 2-(phenylcarbamoyl)phenyl pyrazine-2-carboxylates. These were evaluated in vitro for the activity against fungi and Gram-positive and Gram-negative bacteria. All derivatives showed significant antibacterial activity against Gram-positive strains (MIC ≥ 0.98 µmol/L) including methicillin-resistant Staphylococcus aureus. The most active molecule was 5-chloro-2-(3-chlorophenylcarbamoyl)phenyl pyrazine-2-carboxylate. With one exception these esters were at least partly active against fungi tested strains, in particular against mould strains (MIC ≥ 1.95 µmol/L). The most active antifungal agent overall proved to be 2-(4-bromophenylcarbamoyl)-4-chlorophenyl pyrazine-2-carboxylate.
Export Options
About this article
Cite this article as:
Kratky Martin, Vinsova Jarmila and Buchta Vladimir, In Vitro Antibacterial and Antifungal Activity of Salicylanilide Pyrazine-2- carboxylates, Medicinal Chemistry 2012; 8 (4) . https://dx.doi.org/10.2174/157340612801216346
DOI https://dx.doi.org/10.2174/157340612801216346 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Infectious Complications with Anti-TNFα Therapy in Rheumatic Diseases: A Review
Recent Patents on Inflammation & Allergy Drug Discovery An Update on Natural Products with Carbonic Anhydrase Inhibitory Activity
Current Pharmaceutical Design Green Formation of Novel Pyridinyltriazole-Salicylidene Schiff Bases
Current Organic Synthesis A Review of Molecular Modelling Studies of Dihydrofolate Reductase Inhibitors Against Opportunistic Microorganisms and Comprehensive Evaluation of New Models
Current Pharmaceutical Design In Silico Studies Most Employed in the Discovery of New Antimicrobial Agents
Current Medicinal Chemistry Functionally Engineered Nanosized Particles in Pharmaceutics: Improved Oral Delivery of Poorly Water-soluble Drugs
Current Pharmaceutical Design Oral Agents in Multiple Sclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry An Overwiev of ORF Virus Infection in Humans and Animals
Recent Patents on Anti-Infective Drug Discovery In Search of New Cures for Tuberculosis
Medicinal Chemistry Interactions Between Probiotic Dairy Propionibacteria and the Intestinal Epithelium
Current Immunology Reviews (Discontinued) Medicolegal Aspects of Disclosure of Side Effects of Biologic Drugs in Rheumatology: A Pilot Study
New Emirates Medical Journal New Anti-Tuberculosis Drugs: Strategies, Sources and New Molecules
Current Medicinal Chemistry Preliminary Pharmacological Screening of Some Thiosemicarbazide, s-triazole, and Thiadiazole Derivatives
CNS & Neurological Disorders - Drug Targets Antimycobacterial Activity: Synthesis and Biological Evaluation of Novel Substituted (3E,5E)-3,5-diarylidene-1-phenethylpiperidine-4-one Derivatives
Letters in Drug Design & Discovery Computational Evidence for the Reactivation Process of Human Acetylcholinesterase Inhibited by Carbamates
Combinatorial Chemistry & High Throughput Screening Nasal Polyposis: An Overview of Differential Diagnosis and Treatment
Recent Patents on Inflammation & Allergy Drug Discovery Leishmanicidal Activity of New Megazol Derivatives
Medicinal Chemistry Synthetic Aspects and First-time Assessment of 2-amino-1,3-selenazoles Against Mycobacterium tuberculosis
Letters in Drug Design & Discovery Administration of Exogenous Surfactant and Cytosolic Phospholipase A2α Inhibitors may Help COVID-19 Infected Patients with Chronic Diseases
Coronaviruses Structure-based Drug Design Targeting Biosynthesis of Isoprenoids: A Crystallographic State of the Art of the Involved Enzymes
Current Protein & Peptide Science